Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics.
Galbiati A, Dorten P, Gilardoni E, Gierse F, Bocci M, Zana A, Mock J, Claesener M, Cufe J, Büther F, Schäfers K, Hermann S, Schäfers M, Neri D, Cazzamalli S, Backhaus P.
Galbiati A, et al. Among authors: zana a.
J Nucl Med. 2023 Dec 1;64(12):1934-1940. doi: 10.2967/jnumed.123.266007.
J Nucl Med. 2023.
PMID: 37734838